Last reviewed · How we verify
ATM Kinase Inhibitor AZD1390 — Competitive Intelligence Brief
phase 1
ATM kinase inhibitor
ATM
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
ATM Kinase Inhibitor AZD1390 (ATM Kinase Inhibitor AZD1390) — Children's Oncology Group. ATM kinase inhibitor
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ATM Kinase Inhibitor AZD1390 TARGET | ATM Kinase Inhibitor AZD1390 | Children's Oncology Group | phase 1 | ATM kinase inhibitor | ATM |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (ATM kinase inhibitor class)
- Children's Oncology Group · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ATM Kinase Inhibitor AZD1390 CI watch — RSS
- ATM Kinase Inhibitor AZD1390 CI watch — Atom
- ATM Kinase Inhibitor AZD1390 CI watch — JSON
- ATM Kinase Inhibitor AZD1390 alone — RSS
- Whole ATM kinase inhibitor class — RSS
Cite this brief
Drug Landscape (2026). ATM Kinase Inhibitor AZD1390 — Competitive Intelligence Brief. https://druglandscape.com/ci/atm-kinase-inhibitor-azd1390. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab